225Ac-DOTA-daratumumab

Near Add Your Location

Sorting 1 by

Accepting patients

Phase I Study of Escalating Doses of 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
  • Allogeneic Stem Cell Transplant
  • Monoclonal Antibody
  • CD38
  • Phase 1